MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.30
+0.32
+6.43%
After Hours: 5.30 0 0.00% 19:50 09/25 EDT
OPEN
5.02
PREV CLOSE
4.980
HIGH
5.33
LOW
5.01
VOLUME
493.08K
TURNOVER
--
52 WEEK HIGH
12.32
52 WEEK LOW
0.8800
MARKET CAP
104.54M
P/E (TTM)
-4.0760
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
American Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers' pack
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI) -28%, Aurora Cannabis (ACB) -23%, NanoVibronix NAOV -15%.
Seekingalpha · 3d ago
Capricor Therapeutics Reports Will Present Results From HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At International World Muscle Society Virtual Congress 2020 Oct. 1 At 12:30 p.m. EDT
Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced
Benzinga · 3d ago
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
\--Final 12-Month Results from Phase II Trial to be Presented on October 1--LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment
GlobeNewswire · 3d ago
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that Linda Marbán, Ph.D
GlobeNewswire · 09/10 14:15
LD Micro: 360 Companies--Set to Present this Week.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 09/01 21:34
Capricor Therapeutics to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it will
ACCESSWIRE · 08/31 14:00
Capricor Therapeutics Inc Unit, Cedars-Sinai Medical Center Entered Into Amendment To Exclusive License Agreement
-Reuters
Reuters · 08/25 20:36
Why Capricor Therapeutics Is Trading Higher Today
Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher on Tuesday after the company announced the U.S. Food and Drug Administration has accepted its investigational new drug application for a Phase 2 clinical trial of CAP-1002 in patients with COVID-19
Benzinga · 08/25 15:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CAPR. Analyze the recent business situations of Capricor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CAPR stock price target is 10.50 with a high estimate of 12.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 959.12K
% Owned: 4.86%
Shares Outstanding: 19.72M
TypeInstitutionsShares
Increased
9
217.01K
New
21
211.48K
Decreased
2
676
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Director
Frank Litvack
President/Chief Executive Officer/Director
Linda Marban
Chief Financial Officer/Chief Accounting Officer
Anthony Bergmann
Executive Vice President/General Counsel
Karen Krasney
Vice President
Thomas Copmann
Vice President
Houman Hemmati
Vice President
Luis Rodriguez-Borlado
Vice President - Research & Development
Rachel Smith
Other
Deborah Ascheim
Director
Joshua Kazam
Independent Director
Earl Collier
Independent Director
George Dunbar
Independent Director
Louis Grasmick
Independent Director
Louis Manzo
Independent Director
David Musket
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.